Novel and highly sensitive immunoassay for total hepatitis B surface antigen, including that complexed with hepatitis B surface antibody
Authors:
- Akihiro MatsumotoAMAkihiro Matsumoto
- Masayasu ImaizumiMIMasayasu Imaizumi
- Yasuhito TanakaYTYasuhito Tanaka
- Shuhei NishiguchiSNShuhei Nishiguchi
- Hiroshi YatsuhashiHYHiroshi Yatsuhashi
- Takehiko IshidaTITakehiko Ishida
- Kazushige MoriyamaKMKazushige Moriyama
- Katsumi AoyagiKAKatsumi Aoyagi
- Eiji TanakaETEiji Tanaka
- 26 July 2016
- journal article
- research article
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 52 (3) , 376-384
Abstract
Background Hepatitis B surface antigen (HBsAg) is used as a clinical marker of hepatitis B virus (HBV) infection. However, conventional HBsAg assays have so far failed to accurately detect HBsAg in blood because of interference by patient-derived antibodies against HBsAg (HBsAb). Methods We developed a novel, fully automated assay system that can detect total HBsAg in blood, including antigens complexed with HBsAb. The immunoassay inactivates HBsAb via a simple pretreatment step to dissociate the HBsAg molecule from HBsAg–HBsAb complexes and thereby estimate total HBsAg. Accordingly, the test has been termed the “immunoassay for total antigen including complex via pretreatment (iTACT)-HBsAg.” Results The recovery rate of HBsAg in the presence of HBsAb was greater than 87 % at a cutoff value set at 5.0 mIU/mL on the basis of data from 545 healthy controls. Analyses using serial serum samples from 25 HBV carriers who became negative for HBsAg during follow-up showed that the iTACT-HBsAg could detect HBsAg over a period of years despite a loss in detection by conventional assays and was able to detect HBsAg in 39 (53 %) of 73 samples with HBsAb. Conclusions The new iTACT-HBsAg assay appears to detect total HBsAg with high sensitivity, even in the presence of HBsAb, and may useful in identifying subclinical or occult HBV carriers.Keywords
Funding Information
- Japan Agency for Medical Research and Development (15fk0210035h0001)
- Japan Agency for Medical Research and Development (15fk0310012h0004)
This publication has 26 references indexed in Scilit:
- Hepatitis B virus infectionThe Lancet, 2009
- Mortality Secondary to Fulminant Hepatic Failure in Patients with Prior Resolution of Hepatitis B Virus Infection in JapanClinical Infectious Diseases, 2008
- Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriersVirology, 2007
- Coexistence of Hepatitis B Surface Antigen (HBsAg) and Heterologous Subtype-Specific Antibodies to HBsAg among Patients with Chronic Hepatitis B Virus InfectionClinical Infectious Diseases, 2007
- Management of hepatitis BHepatology, 2007
- Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapyHepatology, 2006
- Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNAHepatology, 2000
- Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigenHepatology, 2000
- The clinical significance of surface antigen variants of hepatitis B virusJournal of Viral Hepatitis, 1997
- Hepatitis B Surface Antigen Circulating Immune Complexes (HBsAg‐CICs) in Patients with Bleeding DisordersVox Sanguinis, 1981